| 000 | 01678 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250511210408.0 | ||
| 264 | 0 | _c19910612 | |
| 008 | 199106s 0 0 jpn d | ||
| 022 | _a0385-0684 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNegoro, S | |
| 245 | 0 | 0 |
_a[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. _h[electronic resource] |
| 260 |
_bGan to kagaku ryoho. Cancer & chemotherapy _cMay 1991 |
||
| 300 |
_a1013-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnorexia _xchemically induced |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Small Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aLeukopenia _xchemically induced |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aFukuoka, M | |
| 700 | 1 | _aNiitani, H | |
| 700 | 1 | _aSuzuki, A | |
| 700 | 1 | _aNakabayashi, T | |
| 700 | 1 | _aKimura, M | |
| 700 | 1 | _aMotomiya, M | |
| 700 | 1 | _aKurita, Y | |
| 700 | 1 | _aHasegawa, K | |
| 700 | 1 | _aKuriyama, T | |
| 773 | 0 |
_tGan to kagaku ryoho. Cancer & chemotherapy _gvol. 18 _gno. 6 _gp. 1013-9 |
|
| 999 |
_c1857609 _d1857609 |
||